XML 73 R62.htm IDEA: XBRL DOCUMENT
v3.7.0.1

Investments in Preferred Stock - Additional Information (Details) $ / shares in Units, $ in Thousands |  | 1 Months Ended | 3 Months Ended | 6 Months Ended |
--- | --- | --- | --- | --- | ---
Mar. 10, 2017 | Mar. 31, 2017 USD ($) shares | Jun. 30, 2016 $ / shares shares | Jun. 30, 2017 USD ($) shares | Jun. 30, 2017 USD ($) $ / shares shares | Jun. 30, 2016 USD ($) $ / shares | Dec. 31, 2016 USD ($)
Schedule of Investments [Line Items] |  |  |  |  |  |  |
Fair value of financial assets measured at fair value on a recurring basis |  |  |  | $ 269,759 | $ 269,759 |  | $ 335,307
Noncash dividend income on preferred shares |  |  |  |  | 7,980 | $ 0 |
Purchases of preferred stock and warrants |  |  |  |  | 1,161 | $ 1,167 |
Preferred stock |  |  |  |  |  |  |
Schedule of Investments [Line Items] |  |  |  |  |  |  |
Fair value of financial assets measured at fair value on a recurring basis |  |  |  | $ 144,742 | $ 144,742 |  | 129,545
Fibrocell Science, Inc. |  |  |  |  |  |  |
Schedule of Investments [Line Items] |  |  |  |  |  |  |
Convertible preferred shares issued (in shares) | shares |  | 1,161 |  |  |  |  |
Number of common shares into which warrants are convertible (in shares) | shares |  | 498,843 |  |  |  |  |
Reverse stock split ratio | 1-for-3 |  |  |  |  |  |
Reverse stock split, conversion ratio | 0.3333 |  |  |  |  |  |
Convertible preferred shares, dividend rate |  |  |  |  | 4.00% |  |
ZIOPHARM Oncology, Inc. |  |  |  |  |  |  |
Schedule of Investments [Line Items] |  |  |  |  |  |  |
Preferred shares, stated value (in usd per share) | $ / shares |  |  | $ 1,200 |  |  | $ 1,200 |
Threshold consecutive trading days, conversion of shares |  |  |  |  | 20 days |  |
Preferred shares, dividend rate (in usd per share) | $ / shares |  |  |  |  | $ 12.00 |  |
Preferred shares, dividend rate, for unconverted shares after conversion event (in usd per share) | $ / shares |  |  |  |  | 24.00 |  |
ZIOPHARM Oncology, Inc. | Minimum |  |  |  |  |  |  |
Schedule of Investments [Line Items] |  |  |  |  |  |  |
Preferred shares, conversion calculation, divisor (in usd per share) | $ / shares |  |  |  |  | $ 1.00 |  |
Other Contractual Payments | Upfront and Milestone Payments | ZIOPHARM Oncology, Inc. |  |  |  |  |  |  |
Schedule of Investments [Line Items] |  |  |  |  |  |  |
Collaborative arrangement consideration received, number of preferred shares (in shares) | shares |  |  | 100,000 |  |  |  |
ZIOPHARM Oncology, Inc. |  |  |  |  |  |  |
Schedule of Investments [Line Items] |  |  |  |  |  |  |
Dividend income, number of preferred shares received (in shares) | shares |  |  |  | 3,313 | 6,529 |  |
Noncash dividend income on preferred shares |  |  |  | $ 4,042 | $ 7,965 |  |
ZIOPHARM Oncology, Inc. | Preferred stock |  |  |  |  |  |  |
Schedule of Investments [Line Items] |  |  |  |  |  |  |
Fair value of financial assets measured at fair value on a recurring basis |  |  |  | 142,326 | 142,326 |  | $ 129,545
Fibrocell Science, Inc. |  |  |  |  |  |  |
Schedule of Investments [Line Items] |  |  |  |  |  |  |
Purchases of preferred stock and warrants |  | $ 1,161 |  |  |  |  |
Fibrocell Science, Inc. | Preferred stock |  |  |  |  |  |  |
Schedule of Investments [Line Items] |  |  |  |  |  |  |
Fair value of financial assets measured at fair value on a recurring basis |  |  |  | $ 2,416 | $ 2,416 |  |

X
- Definition Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258 + Details
Name: | us-gaap_AssetsFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of cash outflow to acquire investments classified as other. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireOtherInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount per share used to calculated dividend payments on preferred stock. + References No definition available. + Details
Name: | us-gaap_PreferredStockDividendRatePerDollarAmount
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage rate used to calculate dividend payments on preferred stock. + References No definition available. + Details
Name: | us-gaap_PreferredStockDividendRatePercentage
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares of preferred stock issued as dividends during the period. Excludes stock splits. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644 + Details
Name: | us-gaap_PreferredStockDividendsShares
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_PreferredStockParOrStatedValuePerShare
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ScheduleOfInvestmentsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 4 -Subparagraph (SAB TOPIC 4.C) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770 + Details
Name: | us-gaap_StockholdersEquityNoteStockSplitConversionRatio1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:pureItemType
Balance Type: | na
Period Type: | duration

X
- Definition Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770 + Details
Name: | us-gaap_StockholdersEquityReverseStockSplit
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares of preferred stock of a collaborator received by the entity as consideration. + References No definition available. + Details
Name: | xon_CollaborativeArrangementConsiderationReceivedPreferredShares
Namespace Prefix: | xon_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Total number of convertible preferred shares issued to shareholders. May be all or portion of the number of convertible preferred shares authorized. + References No definition available. + Details
Name: | xon_ConvertiblePreferredSharesSharesIssued
Namespace Prefix: | xon_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Convertible Stock, Threshold Consecutive Trading Days + References No definition available. + Details
Name: | xon_ConvertibleStockThresholdConsecutiveTradingDays
Namespace Prefix: | xon_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of dividend income included in net income that results in no cash flow. + References No definition available. + Details
Name: | xon_NoncashDividendIncome
Namespace Prefix: | xon_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Divisor of calculation used to convert preferred shares into common stock. + References No definition available. + Details
Name: | xon_PreferredStockConversionRateDivisor
Namespace Prefix: | xon_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount per share used to calculate dividend payments on preferred stock for unconverted shares after a conversion event. + References No definition available. + Details
Name: | xon_PreferredStockDividendRatePerDollarAmountUnconvertedShares
Namespace Prefix: | xon_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of common shares into which warrants can be converted. + References No definition available. + Details
Name: | xon_WarrantsNumberOfCommonSharesIntoWhichWarrantsCanBeConverted
Namespace Prefix: | xon_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=us-gaap_PreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=xon_FibrocellMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=xon_ZiopharmMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=xon_OtherContractualPaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=xon_UpfrontAndMilestonePaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xon_ZiopharmMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | invest_InvestmentAxis=xon_ZiopharmMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | invest_InvestmentAxis=xon_FibrocellMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |